DaVita Inc. (DVA) Earnings Call Transcript & Summary
February 11, 2021
Earnings Call Speaker Segments
Jim Gustafson
executiveThanks for joining us, and welcome to the conference call for our fourth quarter. We're glad you continue to follow our company. My name is Jim Gustafson, and I serve as Vice President of Investor Relations. With me on the call are Javier Rodriguez, who is our CEO, and Joel Ackerman, our CFO. I want to point out that we might make forward-looking statements today, as defined under federal securities laws. Each of those statements carries known and unknown risks along with uncertainties, and those factors could lead to actual results that differ materially from what the forward-looking statements describe. If you'd like more information about such risks and uncertainties, please look at the press release for our fourth quarter earnings as well as the filings we make with the SEC, which include our latest annual report on Form 10-K, later quarterly reports on Form 10-Q, and any other documents we file with the SEC after that. The forward-looking statements we make rest on information available to us right now, and we have no intention, and take on no obligation, to revise those statements, unless the law demands it. We also want to remind you that some of what we discuss on this call involves non-GAAP financial measures. You can find a reconciliation between those non-GAAP measures and the closest comparable GAAP financial measures in the earnings press release we filed with the SEC, which is also posted on our website. At this point, I'll hand the call over to Javier Rodriguez.
Javier Rodriguez
executiveAppreciate it, Jim. Hello everyone, and thanks for being here this afternoon as we walk through how we did in 2020 and what we're thinking about for 2021. At DaVita, the past year really put a spotlight on our caregivers and how devoted they are to people living with kidney disease. The pandemic brought obstacles none of us could have pictured just 12 months earlier. Those obstacles—whether in patient care, how we operate, or our finances—opened doors for us to draw on the strength of our teams and platforms to stand behind our patients and the broader community. Looking back at the year, 3 items in particular come to mind. Number one, how much our caregiver teams prioritized the health and safety of those we treat; number two, the ingenuity and fresh thinking our organization demonstrated as we adjusted to a shifting environment; and number three, the compassion, understanding, and commitment our teams showed one another and those in our care. Even with all that positive effort in 2020, COVID's difficulties haven't gone away. The most recent stretch has proven especially hard on our patients and care teams. The outsized toll the virus takes on people with underlying conditions and on older individuals keeps showing up within the dialysis community. The elevated patient mortality figures we mentioned three months ago regrettably sped up during November and carried on into January. Our estimate is that the patient census we ended 2020 with came in roughly 7,000 below where it would have landed without COVID in the picture. Looking ahead, certain forward-looking signals—like declining new COVID infections, reduced hospitalizations, and the vaccination push we've seen lately—give us reason for optimism; that brings me to our clinical priority around vaccines. For the last several months, we've been working with the federal government, with state agencies, and with the CDC to find pathways for our caregivers and patients to obtain the vaccine. Our setup makes us especially well-suited to deliver vaccines safely and efficiently inside our clinics, thanks to our infrastructure, our clinical know-how from giving flu shots annually, and our capacity to track patients' health on a weekly basis. Talks with the CDC and the federal government continue, and we're in the process of getting connected to their direct vaccine distribution system so we can launch the instant we receive approval. In places such as Minnesota and a number of large counties throughout California, where we've managed to lock in direct allocation, as many as 70% are getting vaccinated, partly because we have access and partly because acceptance tends to run higher when patients witness fellow patients getting the shot. In much of the remaining parts of the country, the logistics of signing up and reaching access at standalone vaccine locations has proven difficult for a lot of patients. So our end goal is still to secure direct allocation from the federal government. Now let's turn to how we performed financially. Even with COVID's hurdles, we substantially beat our initial financial guidance for 2020. We understood it would be a demanding year for generating profit growth, what with the calcimimetic revenue decline and the expense of battling the ballot initiative in California weighing on us. Once the pandemic struck, the difficulty of achieving growth became even greater, since COVID introduced a great deal of unpredictability into our financial results. Even with that unpredictability, we achieved an increase in adjusted operating income in the double digits, setting aside the effects of calcimimetics, ballot cost and net COVID impact. We posted a rise of 34% in adjusted earnings per share from continuing operations and produced free cash flow from continuing operations of nearly $1.2 billion, at the same time as we gave back $1.4 billion to shareholders via our share buyback. Looking at Q4 on its own, we saw a net COVID impact of about $60 million, which came in above what we had expected. During the first 3 quarters of the year, the net COVID impact was smaller, because the added costs tied to COVID were balanced out by reduced benefits, travel and G&A spend. In Q4, we observed a faster pace of impact from higher mortality emerging after the holiday season, along with fewer offsets in benefits and G&A expenses. This produced a negative COVID impact roughly $35 million greater than we had anticipated, which pushed our Q4 earnings under the guidance range we gave last quarter. If you set aside that larger COVID impact in Q4, our earnings would have landed in the middle of our guidance range. Turning to the year ahead, our guidance range will be $7.75 to $8.75 per share, which includes the COVID impact we expect and reflects our confidence in the underlying earnings growth of our business. We believe our core performance in 2020 gives us a solid foundation for achieving the long-term financial goals. Before I pass it to Joel to go through our quarter and our outlook in more detail, let me say a few words about our recent Medicare Advantage enrollment. As a reminder, 2021 marks the first year in which existing dialysis patients can choose to enroll in the Medicare Advantage plan. In the past, MA coverage for ESRD had been restricted only to patients who were already enrolled in MA plans prior to kidney failure or to certain patients in MA Special Needs Plans. By the end of 2020, the share of our Medicare patients enrolled in MA plans was nearing 30%; and according to our preliminary enrollment data, we now anticipate that our percentage of MA patients among Medicare patients will be in the mid-30s in 2021, which remains under the national average. As you would expect, the new enrollment was mostly for Medicare patients who previously lacked secondary coverage, since these patients will gain from the expanded benefit of MA and the cap on out-of-pocket expenses. The growth in the ESRD MA population opens up opportunities for us to build further momentum toward value-based care that we've been investing in; this is an exciting trend, and we're eager to lead the way with our payer and nephrology partners to deliver comprehensive care to our patients, which we believe will help lead to better clinical outcomes and lower overall cost of care. The range we've given for 2021 guidance takes into account the costs we anticipate and the investments we'll make in order to build out our care model for our value-based agreement. At this point, I'll pass things along to Joel.
Joel Ackerman
executiveThanks, Javier. I'll start by adding a bit more detail on how Q4 turned out, and after that I'll turn to what we're expecting for 2021. When we look at the whole of 2020, we came in ahead of what we originally thought, and the underlying ability of this business to generate earnings is still solid. That said, what we saw in Q4 shows the significant drag created by the most recent wave of COVID. We posted operating income of $382 million, while earnings per share from continuing operations came to $1.67, which fell short of what we told you to expect on our previous earnings call. At the midpoint of our adjusted EPS guidance, we had assumed COVID would create a net headwind of roughly $25 million. But as Javier mentioned, what actually happened was a hit of about $60 million. If you set COVID aside, our EPS from continuing operations would have landed in the middle of our adjusted guidance range. Compared with Q3, we saw several shifts: first, changes in first mortality, which compounded across the year; second, fewer expense offsets during the quarter, especially those tied to healthcare costs for our teammates, which had helped soften the net financial hit from COVID back in Q2 and then again in Q3; and third, greater direct COVID-related costs, such as certain benefits aimed at helping our frontline teammates cope with the hardships of COVID, plus higher spending on PPE. Beyond COVID, other noteworthy items this quarter include non-acquired growth of negative 0.3%, which came from the monthly mortality trend getting worse as the quarter went on. Revenue per treatment rose this quarter because of the usual fluctuations in Medicare reimbursement along with seasonality. Patient care costs were higher on a sequential basis, mainly because of the various COVID effects I just described; G&A was lower sequentially, largely from removing ballot cost; and our international business kept delivering core profit, though it was offset by a $6 million foreign exchange loss. During Q4, we bought back 4.2 million shares of our common stock. On top of that, so far in 2021, we've repurchased about 1.1 million shares, which puts our share count today at roughly 109 million. When you're working out our diluted share count for your models, remember to factor in the dilutive impact of EPS from outstanding equity awards, which came to about 4.3 million shares in Q4. Now let me look ahead to 2021. As the press release shows, we're guiding to adjusted operating income of $1.675 billion to $1.825 billion, adjusted earnings per share of $7.75 to $8.75, and free cash flow of $900 million, $1.15 billion. Our guidance ranges are broader than what you'd normally see from us. That reflects just how much uncertainty there is around how COVID could affect our 2021 results. At the midpoint of the range, we've built in an estimated net COVID-related cost of about $200 million. The main reason the impact keeps growing compared with 2020 is that treatment volume is falling because of higher mortality. We're basing our guidance on the idea that elevated mortality will persist through the first half of 2021, then move back toward pre-COVID levels during the second half of the year thanks to broad uptake of an effective vaccine. That said, COVID brings a much greater degree of uncertainty into our forecast, and some scenarios exist in which we could end up performing outside of this range. If we set aside COVID's effects, we think 2021 will deliver another year of solid underlying operating income growth along with strong free cash flow, and we intend to keep investing in our strategy as well as in innovation. Now let me give a bit more color on our outlook. Ballot cost ought to be a meaningful year-over-year tailwind — we spent roughly $67 million in 2020 on defeating the ballot initiative in California. Since 2021 isn't a general election year, we don't anticipate that expense recurring. Calcimimetics ought to be fairly flat year-over-year, though its quarterly contribution will be spread evenly across 2021 instead of the declining pattern we saw in 2020; given that calcimimetics is now a permanent piece of our Medicare run rate, we won't be calling out its financial impact anymore going forward. Other swing factors include the benefit of growing Medicare Advantage enrollment, which is offset by what we're investing in our value-based program. Those investments cover G&A costs tied to improving our model of care plus start-up costs tied to new contracts. A few more quick points on 2021. We anticipate that our capital expenditures in 2021 will look similar to our 2020 spend. As a reminder, our current run rate interest expense comes to $60 million to $65 million per quarter. Absent any material changes from the new administration, we expect tax rates to stay between 26% and 28%. And as always, Q1 has 2 fewer treatment days than Q4, along with higher bad debt and payroll taxes. On a year-over-year basis, Q1 will have 0.6 fewer treatment days than last year because of the leap year; with that, operator, please open the line for Q&A.
Justin Lake
analystI'd like to build on what we discussed about 2021, and first just confirm that I grasp a few of the dynamics at play; Joel, you mentioned $200 million tied to COVID. Does that line up with — when I add up sequestration plus the COVID expenses and the COVID-related savings, my calculation gives $60 million for this year? That would leave $140 million from mortality?
Joel Ackerman
executiveCorrect, and let me point out to everybody that COVID comes with a great deal of uncertainty. That's why we aimed to be useful by centering on a scenario in the middle of our range. But indeed, that $200 million can be compared on an apples-to-apples basis with a figure of roughly $60 million for 2020.
Justin Lake
analystAll right. That means deaths account for the rest of the $140 million. Then, regarding Medicare Advantage, did you mean those expenses work as an offset? Is Medicare Advantage on the whole basically a net wash, or does some advantage remain? Any detail you could provide about how significant that is would be useful.
Joel Ackerman
executiveYeah. My view of MA is this: the penetration rate rose — roughly 5%, I'd say. In an ordinary year, we'd typically observe a couple of percent, while 3% comes from the Cures Act and from the fact that certain patients of ours gained access for the first time. When we consider the benefit from that 3%, it falls within the same band as the additional spending we are undertaking in 2021 tied to expansion of our value-based contract operation, which we refer to as IKC, or Integrated Kidney Care. Thus a gain from that additional 3%, plus a commitment connected to Integrated Kidney Care, and those 2 items sit approximately in the same range; so regard them as a wash when it comes to the effect on 2021 OI growth.
Justin Lake
analystUnderstood; now for my final question. Look, I've followed this company for quite a while, and thinking through the decremental margins tied to members we lose or patients with treatments has never been easy for me. My assumption is that deaths are concentrated more heavily among Medicare patients — is that point number one, and can you verify it? Then second, could you walk us through — that $140 million figure really helps, but what revenue is being given up there, so we can attempt to grasp the decremental margin tied to that lost business and perhaps consider what it might look like once conditions return to normal?
Joel Ackerman
executiveAbsolutely; first, allow me to clarify — you keep referring to the $140 million. Let me explain our view of the $200 million. In many respects, it mirrors what happened during 2020. Our COVID impact would fall into 3 buckets. The first covers direct COVID-related costs — consider the enhanced benefits provided to teammates to assist with hardships caused by COVID, consider greater spending on PPE. That's bucket one. The offsets make up bucket 2 — reduced T&E, Medicare sequestration revenue, and lower benefits as a self-insured employer. What we observed during 2020 was that these were sizable figures, yet they typically canceled one another out. That didn't hold true each quarter, which explains the significant swing you notice between Q3 and Q4. Yet across the full year, those 2 figures canceled out, and the net effect for 2020 came from an accumulating loss of treatments tied to certain patients dying because of COVID; so the 2020 impact from mortality can be thought of as $60 million. Under the scenario we described, that $60 million rises to $200 million in the coming year; and once more, during 2021, we expect roughly that higher costs get offset by the offsets, even though costs will decline and offsets will decline too; the character of those costs will also shift somewhat. We expect PPE to stay elevated since the per-unit cost of certain PPE items remains high. Clearly, sequestration stays in place for Q1, but after that it disappears. We believe T&E stays low, while health benefits for teammates will decrease. So once more, direct costs plus offsets net to approximately 0, and the $200 million reflects the mortality impact. Now to your core question. Two points. Yes, patients dying from COVID tend to be older than our typical patient. Consequently, they are more apt to be Medicare, and the commercial mix in that group is smaller. As for how this affects our cost structure, modeling it is difficult. The answer really hinges on the location of those patients, the duration involved, and the timeframe over which this plays out. Still, it's fair to characterize our G&A as fairly fixed, whereas with our patient care costs, the bulk of what we spend on patients is variable.
Pito Chickering
analystFollowing up on what Justin asked, suppose we use the middle of the guidance range and put $200 million on top of it — normally, more than 40 to 50% of your operating income for the year comes in the back half. So should we conclude that operating income for the back half of the year ought to exceed $975 million?
Joel Ackerman
executiveNo. Well, do you mean if we leave out COVID?
Pito Chickering
analystRight, right. Since, as you mentioned, COVID's effect is felt during the first six months and then only slightly during the last six months. So I'm just wondering, could you help me reason through the second half, roughly setting COVID aside, or actually even using your own assumptions, roughly what operating income ought to look like in that period?
Joel Ackerman
executiveAbsolutely; let me make clear what we meant when we referred to the first half. In the scenario we were describing, the point we were making is that the extra deaths showing up among our patients because of COVID would be heavily clustered in the first half; however, the treatments lost tied to those patients who sadly died early, that persists into the second half and sadly, will persist into 2022 as well. So those treatments are gone. And what you'd observe in the second half is — with luck, you'd observe NAG reaching its low point and beginning to rise during the second half, yet the lost treatments will need some time to work their way through the system; therefore I don't believe you can claim the second half won't feel any COVID effect, it definitely will feel a COVID effect.
Pito Chickering
analystAll right. That leads nicely into the 2021 guidance. Could you assist us — since you folks didn't give revenue guidance, could you help us think through approximately where treatment growth in the first quarter will land, and then where you're modeling the fourth quarter treatment growth ranges? Has ESRD incidence come back to normalized levels? And are you noticing some modest tailwinds from a shortage of kidney transplants?
Joel Ackerman
executiveYes. So when you consider all the other elements affecting NAG regarding treatment and volume — regarding transplant volume and new-to-ESRD admits, those things have mostly gone back to normal. So we don't expect much of an effect from that. So the 2021 NAG story mostly centers on the mortality question. When you consider Q1, and I'll speak in terms of NAG, we expect NAG to keep declining in Q1 and then once more in Q2. And that's really caused by this scenario we described of rising mortality. And after that, it's difficult to know where it will bottom out. Again, there's considerable uncertainty here; but regarding trying to gauge what NAG might look like in Q2, you could expect something as low as negative 2% or even negative 3% for that 1 quarter, and then it will begin to recover from there. If you considered the full year 2021 NAG, again, we're not providing guidance on NAG, but just to help you all think about it, I believe it's safe to think of a negative NAG for the full year, certainly, probably — I think it's reasonable to model it as somewhere between negative 1% and negative 2%; and then you don't see NAG actually return — remember NAG is a year-over-year figure, so you wouldn't see it come back to normal until mid-2022. And then the one other item I'd mention about NAG is once the mortality has moved through the system in terms of — on a quarterly basis, we're not seeing excess mortality and once you've had a full year for the lagging effect of NAG to play through, then you would expect us to have a bit of a tailwind tied to NAG. The unfortunate mortality that we've seen because of COVID should result in lower mortality over the next few years since some of the patients who died of COVID would have otherwise died in 2022 or 2023, et cetera. So you'll certainly see a real headwind on NAG in 2021, you'd expect a bit of a hangover from that in 2022. However, as we move past the midpoint of 2022 — and once more, everything here depends on our assumption that vaccines are effective and that our patients can obtain them — you would begin to observe a NAG running above typical levels during that latter portion of 2022. I also want to say sorry for the sheer quantity of figures I've been citing and for how bewildering this may come across. So should any part of that have been unclear, please do reach out with a follow-up.
Andrew Mok
analystTo start, I'd like to revisit the MA topic. Could you elaborate on a few of those value-based contracts you managed to secure alongside your MA partners for 2021, covering both how they're built and how significant they are to your patient population?
Javier Rodriguez
executiveAndrew, I'll take that one. The truth is, our structures vary quite a bit. Looking back, we originally had the Special Need Plans, and later we brought in the ESCO models — those were the CMMI models — and those are currently phasing out. Then naturally, CMMI introduced fresh models. Within that, there are the 4 options CMMI offers, plus we had the executive order. So on the government side, there's considerable innovation happening around value. On the commercial side, we're obviously doing more now with our MA partners. As a result, we've set up arrangements ranging from shared savings all the way to something resembling a full cap. So as you can tell, the options are broad. What matters most to take away is our dedication to shifting toward value-based care, and we're proceeding in small steps to ensure we can fulfill every commitment we're making. That's the reason we're investing, so we can deliver regardless of which format emerges. Does that answer your question, Andrew?
Andrew Mok
analystYes, could you give us a patient count reflecting the mix—what currently sits inside value-based arrangements?
Javier Rodriguez
executiveWe have one, though it will swing considerably given the filing of every one of those government CMMI products. As a result, we don't know how that entire process will unfold, since they begin in April and it's unclear how many patients will sign up. That, then, will represent the bulk and the biggest portion of it.
Andrew Mok
analystUnderstood. All right, that's useful; and could you speak in a wider sense about the way the pandemic along with excess mortality is shaping your approach to patient clinic optimization and, more broadly, home dialysis? Are you seeing those two efforts speed up across the coming 12 to 18 months?
Javier Rodriguez
executiveThanks for that. The brief response is no, since what matters most is that patients and physicians have the modality of choice that they consider right for proper care. That comes first and is the initial consideration. Second, naturally, where a region has been hit hard, we examine it to determine the capacity available at those centers; so we are reviewing that carefully. Yet as you might expect, most of these communities depend on our centers, and we must act very responsibly, because even with mortality, other patients remain there; and as you're aware, for a very long time, we've kept several hundred centers that have been losing money. After that, deciding whether to shut a center is a very tough call, and not one we make casually.
Andrew Mok
analystUnderstood. Then, finally, you said vaccination rates reach 70% among your patients in certain areas. Is there a vaccination rate for your entire patient population as of now?
Javier Rodriguez
executiveYes. The rate for patients has been disclosed, and the rate for teammates is now beginning to enter the 40% range. As I mentioned during the remarks, we are collaborating very diligently with the government, since our hope is to obtain direct allocation. Take the flu — the standard flu vaccine — as an illustration: we achieve nearly 90% throughout the whole cohort, and we accomplish that within an extremely brief timeframe, so we are presenting our case to the government. However, naturally, as you are aware and have read, there is substantial demand among many different groups, so we are attempting to get past that barrier.
Kevin Fischbeck
analystI'd like to dig a bit deeper into those MA investments; from what I hear, they're going to cancel out the gains from that area during this year. Do you have to make these investments just to get in, after which that line of business grows more profitable as time passes? Or is the assumption behind the spending that an additional 5% or 10% of patients will eventually come aboard; meaning you'll need more MA patients to arrive before you can leverage the investment and begin earning a profit? What's the right way to view how the margin for MA patients in a capitated arrangement evolves over time?
Joel Ackerman
executiveYes. There's a great deal we'll find out regarding this across the coming few years, Kevin, though my sense is that a reasonable margin falls somewhere between low and mid-single digits. When you treat it as a full cap form of accounting on certain of these, not all of the revenue gets taken in, which affects the margin. Still, when it comes to margin for each patient, you'd land at roughly the identical dollar figure.
Javier Rodriguez
executiveKevin, perhaps I can jump in briefly, since what we're doing with value-based investments may not be entirely obvious. I tend to think about this in 2 buckets. The first covers things like G&A, software, and care models for non-ESRD conditions—diabetes, mental health, end of life—models that could grow across various frameworks. The second involves start-up expenses tied to every individual contract, which carries custom components: care models, health assessments, and other items unique to each contract. So I hope that clarifies things.
Kevin Fischbeck
analystYes. That answers it. Let me just make sure I follow what you mean by "a little bit." Given what you said about revenue — I believe a typical MA dialysis patient brings in roughly $96,000, at least where premiums are concerned. So when you describe it, are you essentially saying around 85% of that figure represents how you view the revenue? Or would I need to factor in additional adjustments?
Joel Ackerman
executiveIf I were building that model — and keep in mind, there's plenty of uncertainty ahead — I'd suggest thinking of it this way: we earn a margin on whatever portion of the cost isn't dialysis. Picture us as a medical manager and a value-based care provider operating on, let's say, 2/3 of that $90,000, which is the part that isn't spent on dialysis. Dialysis costs stay fairly stable. So I'd take the margin figure and apply it to that 60,000 number.
Kevin Fischbeck
analystAll right, that's useful. So then, I suppose, those 7,000 patients affected by mortality — that works out to roughly 3% of treatments during the quarter. So should we take that to mean you now view a normalized treatment growth rate for the business as 3%? I mean, you folks had been running closer to 2% or even below that as we went into COVID. Is that the level you think things eventually return to once COVID is behind us? Or are you suggesting those other dynamics have normalized, but only as a result of COVID, and once COVID disappears, those factors will reemerge and push industry growth below 3%.
Joel Ackerman
executiveYes. So Kevin, I appreciate the math you're attempting there, which is to take the loss treatment count and work backward to figure out what our normal NAG would have been. That analysis is extremely difficult to pull off. The 7,000 figure was a quarter-end number; so simply multiplying it doesn't work. In fact, it skewed somewhat more toward November and December, when the spike started. So I don't believe you can work backward to a NAG number. Honestly, we're struggling to do that ourselves, because there's a great deal of uncertainty around the question of excess mortality and which of those patients actually died from COVID as opposed to other causes. So I would steer clear of trying to extrapolate to what our underlying NAG is.
Kevin Fischbeck
analystOkay. Then, only one more item from me. As you noted, the outlook is somewhat broader than usual, and I realize COVID brings plenty of unpredictability. Is this really just about the mortality piece? Should that be the main item on our radar? Or do other significant swing factors deserve our attention too?
Joel Ackerman
executiveWell, I'd say several additional swing factors could shape the year; so going through them, clearly the vaccine's effectiveness along with the variants matters, and that feeds into the mortality line. Then there's COVID's possible economic effect and how that might influence private pay mix. Back when the pandemic began, this came up often, and it worried us greatly; our patients have impressed us with how resilient they've been about keeping their coverage, but don't overlook that PPE costs stay a fairly fluid matter, not so much regarding volume utilization as regarding price. More government support could well happen, such as extending the sequestration halt or a similar measure. So those are some items I'd flag for you to watch. Having said that, yes. For 2021, the mortality issue is definitely what's driving our modeling above all.
Lisa Clive
analystA couple of things. First, regarding that $200 million headwind tied to additional COVID mortality — with $140 million of it being incremental — based on your guidance, it seems you're fairly confident you can completely counterbalance it, at least at the midpoint of your OI guidance. I'm trying to figure out the source of these extra cost savings, since your company has operated quite lean for quite some time. So I want to understand what other levers exist, particularly when you anticipate NAG might actually be slightly lower across the year. Then my second thing relates to home modalities. Clearly, the priority is doing right by each patient. But since the pandemic began, have you noticed more interest in home modality? And more specifically, when we consider the move toward home — whether PD or HD — are you identifying these patients soon enough for it to matter regarding whether they remain employed, possibly retain their private insurance instead of leaving their job and either entering COBRA temporarily or moving straight to Medicare? Really, I'm attempting to grasp the longer-term effect on patient mix resulting from increased home use.
Joel Ackerman
executiveCertainly; Lisa, I'll handle the first, and Javier will likely take the second; my understanding of your question is: what's the bridge from 2020 to 2021, considering the headwind? Here's my framework. Suppose you look at our non-GAAP or adjusted OI for 2021, add back $67 million for the ballot initiatives, then add back $60 million for COVID, and then set that against the midpoint of our range with COVID added back; so this — so 19.50, you'd arrive at roughly a 4% growth rate; that's my way of assessing how the core performs year-over-year. For me, 4% represents a solid, stable year for the core, with this highly challenging, highly uncertain calcimimetic COVID layered on top. That 4% is roughly what a typical year looks like for us: low to mid-single-digit revenue growth, steady margins, once again propelled by RPT increases beneath inflation. Solid cost management. I mentioned the MA and the IKC canceling each other out. That's my thinking on the 4% growth. It's simply a stable, steady year obscured by COVID.
Javier Rodriguez
executiveAnd Lisa, let me take the second portion of that, which concerns the home modality. The brief response is that we're very enthusiastic about home modality. Since it truly improves quality of life, our physicians and patients are reacting really favorably. And we're innovating heavily so that when patients are at home, they feel the same confidence and security as they would at the center. So we're creating many tools, such as remote monitoring, telehealth, and other things, so our patients can experience that sense of safety while doing dialysis at home. It keeps expanding substantially. And regarding reaching patients sooner and how that affects mix, the brief response is that this remains a work in progress. We keep collaborating with our physician practices to ensure they're educating patients, and we've created world-class — free for anyone in the community, to access training so you can understand your modality selection. And the hope is, naturally, that you choose early enough that your transition happens without a major spike or without any depression or mental issues while you get used to dialysis.
Lisa Clive
analystAll right, and I've got a single follow-up for Joel regarding the cost structure. Could you remind us where things stand with your Amgen epo deal? I understand a long-term agreement was signed with them. What's the renewal timing on that? And might that be a path toward reduced costs?
Joel Ackerman
executiveSure, Lisa — the contract concludes at the close of 2022. As you're aware, confidentiality agreements have always left us somewhat constrained in what we're able to disclose. Once that contract wraps up, it will definitely be an interesting period with respect to hips and certain other dynamics. So what happens at that point is still to be determined.
Whit Mayo
analystGoing back to how mortality is behaving. I was considering the hospitalizations where the patient doesn't die, and from certain industry figures we've observed — not sure whether this holds up — the hospitalization rate looks like it might be 3 to 4 times greater than the fatalities; and yes, this is risky territory, but it would suggest roughly 20,000 of your patients may have been in the hospital during the same window when you saw that elevated mortality. And I get that it's tough to disentangle whether COVID caused the mortality or whether something else was at play. But broadly, I just kind of wanted to hear your perspective — what you're observing regarding hospitalizations in general and visits that didn't happen. I mean, in aggregate those figures are likely pretty small.
Joel Ackerman
executiveYes. So during the early part of the pandemic, we in fact benefited from fewer missed treatments, which presumably reflects our patients staying away from the hospital. That has mostly gone back to normal, so it isn't really showing up in the treatment numbers at present. I'd point out that one piece of our platform is a reasonably large acute business, and that one has picked up some advantages because of this; so — but as far as the total effect across the year goes, it isn't meaningful.
Whit Mayo
analystAll right, I'll drop the mortality topic. That pretty much wraps things up, I believe. Though one more thing I wanted to ask: I believe you're now back in network with Humana — although technically, you may never have left the network. That's likely the more precise way to put it. Still, anything you can tell us regarding that agreement, and perhaps more generally, an update on the network adequacy adjustments? And any shifts you're noticing in how payers are acting? I'm just somewhat curious about that subject.
Javier Rodriguez
executiveAbsolutely. I'll take that one; it's Javier here. I'd say the excellent result of the Humana negotiation is that each side achieved what it set out to do. Humana and DaVita alike wished to ensure that additional patients gained access, that we kept innovating, and that we kept building what we refer to as the win-win arrangement, which delivered improved outcomes at a lower cost. Regrettably, that involves far more complexity and requires much more time, since extensive analytics are needed to confirm we're positioned for a win-win. Broadly speaking, the MA book, as we mentioned previously, is largely under contract and has been for a good while. The Humana contract's timing simply fell at year-end, and given its scale, it's naturally more involved — but we're extremely pleased with the final result, and we anticipate a multiyear partnership that fulfills this value-based contract.
Whit Mayo
analystAll right, and honestly this is just one final item — Joel, I doubt you're inclined to provide particular quarterly guidance at this point, yet is there any framework for estimating what portion of your earnings might land in the opening half as opposed to the closing half? It would be unfortunate if all of us ended up badly mistaken about how your team is viewing the rhythm of earnings internally.
Joel Ackerman
executiveYeah. See, the first quarter tends to be soft. We face elevated bad debt, bigger payroll taxes, and something else that escapes me right now; even so, I wouldn't — even so, compared with a year ago, things will look quite different, since a year ago the calcimimetics figure genuinely distorted matters, and so did the ballot initiative. Oh right, there are fewer treatment days during Q1, my apologies. Still, I doubt it will be drastic. My sense is the pattern won't diverge much from a typical year. And because the mortality problems we're flagging are going to truly peak during Q1 before declining, treating COVID as fairly evenly distributed over the year isn't unreasonable.
Whit Mayo
analystAlright, so when I consider the first half compared with the second half, do you mean that we ought to use the usual seasonal trends, referencing 2019, 2018, and 2017? Could we treat that as a sensible split separating your first half from your second half?
Joel Ackerman
executiveIf you're focused on the core, then yes, you could reference reasonable patterns from history and how — well, COVID is unpredictable enough across the entire year, and predicting how it will unfold quarter by quarter is difficult; that was clear in Q4. Still, a fairly even distribution throughout the year strikes me as a sensible starting point for a highly uncertain figure.
Javier Rodriguez
executiveWhit, the key premise in that scenario is obviously that if deaths occur early in the year, that pattern keeps going — quite unlike 2020, when the surge actually landed late in the year. So from an analytical standpoint, naturally, that rests on the idea that the vaccines are effective and that Q4 and Q3 appear — closer to normal than things stand at present.
John Ransom
analystSince I always want straightforward responses to complex inquiries, let's consider 2021 against 2020. What percentage of Medicare Advantage did you have in 2020? You've given me the figure for 2021, but how does the earlier year stack up?
Joel Ackerman
executiveAs I recall, our statement was that by the close of 2020, we had nearly reached 30% — excuse me, 30%; at present we're in the mid-30s. And keep in mind, the remainder of the market, which is to say the non-dialysis portion, sits at approximately 40%.
John Ransom
analystSure, but what did '20 average out to? You mentioned the finish, but what's the figure — I recall something in the mid-20s?
Joel Ackerman
executiveIf you figure it shifts about 2 percentage points across the year, you can calculate from there, but it lands in the high 20s.
John Ransom
analystI believe I can manage 30% less 2%. Fine, then.
Joel Ackerman
executiveYou're skilled at making this easier to grasp.
John Ransom
analystYes. I'm a straightforward guy. Staying on that straightforward note, I realize you'll be drawing down part of this benefit. Still, my assumption was that the rate increase comes to roughly $50 per treatment. Does that sound absurd, going from Medicare fee-for-service over to Medicare Advantage?
Joel Ackerman
executiveYes. Whit — apologies, John, for some time now we've steered clear of addressing that figure. Picture us seated opposite an MA plan, and we simply don't want them to learn precisely what the typical rate equals; therefore, no comment from us on that. Our aim was to assist with how one might project '21 against '20, and that's the reason we highlighted the IKC investment as similar in magnitude. Thus, you can observe that across the two years they essentially offset each other. And once more, that offsetting applies against the additional 3% of MA growth, rather than the entire 5%. So the 2% we receive annually, consistently, will be ours to enjoy. However, the — regarding the rate gap separating MA and standard Medicare fee-for-service, we'd rather not say anything.
John Ransom
analystAbsolutely. Next, something I think hasn't gotten enough attention is the incredible work your staff is doing. So if you had to estimate, what share of your employees do you think will say yes to getting the shot before the year is over?
Javier Rodriguez
executiveThat's a terrific question, John. We've been polling people, and when it comes to flu shots, we land in the high 80s, low 90s. So this is clearly a one-of-a-kind situation they're navigating, and they've witnessed what's happening with COVID. What our figures tell us at this moment is a bit below what we typically see for flu, and then the real question is, once the vaccine is available, if it's easy to access and you build up steam, will we get back to those typical flu numbers? Honestly, we don't have the answer. But as of now, about 40% of our field workforce has gotten the vaccine.
John Ransom
analystAbsolutely. And if we return to the topic of labor briefly. In terms of burnout, temporary staff, and exhaustion, would you say they have turned the corner — would you say they have turned the corner, so to speak. I mean, does this present an atypical difficulty for you? Or do you believe it persists into next year — or, in fact, this year?
Javier Rodriguez
executiveWell, John, I truly value the compassion you show toward this team, since their dedication, resilience, and sheer commitment have been nothing short of remarkable and a source of inspiration for all of us; however, no, they are genuinely still in the middle of it. That surge at the close of the year and the start of this one proved sharper and more severe than anybody could have expected. And so they have been laboring, laboring, laboring while striving to keep everyone protected. Thus the weariness is genuine, the psychological toll and the bond they share with our patients and witnessing that mortality we have discussed is an emotionally weighty and extremely heavy burden to bear; and therefore I believe this will carry ramifications for the whole caregiving system for many years ahead.
John Ransom
analystYeah, that's right. And finally, on the topic of global risk — you all spent roughly 8 years with your previous DaVita Medical Group — how are you thinking about managing that 2/3 downstream portion that isn't directly under your control? Does it come down to Medicare rates? Downstream risk contracts? Or is the idea simply that since we control the patient, we can make them healthier, and they'll interact with the health system however they do, but we believe that by having a front-line seat with that patient, we can somewhat steer their behavior toward better health compared with the average we're aiming against?
Javier Rodriguez
executiveLet me take that. And then, Joel, feel free to add on, because I'm not entirely certain I follow exactly where you're headed. But ultimately, I believe the response is — my — that 2/3, we'll handle part of it ourselves within our centers, in areas where we believe we can contribute substantial value. And then in other areas, we'll work with providers we trust deeply, so I think it'll be a hybrid approach, and we're learning quite a bit, and we've gained a lot of knowledge through our ESCOs about where our strengths lie. So for instance, if you conduct a health assessment in the center, when you've got a patient for 4 hours, you can be very thorough, and you can have the systems in place to ensure you deliver the right therapy to intervene, and that way you get the twofer there. And in other parts of health care, as you're aware, the difficulty is first, getting a hold of the patient; and second, actually doing something about it — intervening. And so we do possess, let's say, a strategic advantage when it comes to access to the patient. Did that address your question?
John Ransom
analystOkay, but suppose someone walks into a hospital nearby — are we talking about the Medicare rates you're using in that assumption? I'm simply attempting to get a handle on how the insurance company handles downstream contracting regarding getting into the broader health care system? And in what way you either...
Javier Rodriguez
executiveI believe I follow what you're asking. Typically within the contract...
John Ransom
analystYou mentioned the margins in that remaining two-thirds. So I'm just attempting to work out how you achieve that margin there when two-thirds of spending is involved?
Javier Rodriguez
executiveRight. Now I follow you. Typically, the agreement presumes you gain access to the payer's network, and essentially you're pursuing utilization plus improved care, meaning you're aiming to bring utilization down rather than price.
Gary Taylor
analystI was hoping to get a clearer sense of how big this shift toward risk-taking among your MA members actually is. Can you share any figures about what lies ahead — for instance, what share of MA enrollment sits in a capitated arrangement or a meaningful gain-sharing arrangement, as opposed to merely a few points tied to care quality — and how that has compared over time? Looking at 2021, does a substantial slice of your MA patients fall under something resembling a capitated contract?
Joel Ackerman
executiveThe scale remains fairly modest, though it keeps expanding. Honestly, at a fundamental level, we regard this line of business as aligned with where health care ought to be heading. The opportunity is sizable, and we believe we have earned the right to succeed, given what Javier described regarding our capacity to provide quality and oversee care on the non-dialysis side at present; it is still fairly modest. We are watching it quite closely. To my mind, the key thing I want to stress is that we treat this as a fresh business, not merely another mechanism for funding dialysis costs; yet when it comes to current scale, it remains modest.
Gary Taylor
analystAlso, when it comes to direct contracting growing, clearly you have professional global this year, and next year there's a limited theoretical rollout across 10 cities for geographic direct contracting. That means the same health plans will now be bearing risk for your Medicare fee-for-service population. If direct contracting expands and succeeds, would you expect to enter risk-based contracts? Or do any exist at present?
Javier Rodriguez
executiveThat's an intriguing idea. At the end of the day, I'd say it's probably not going to happen, yet we'd be willing to look into it, since if an upstream party assumes the risk — like the scenario you described with direct contracting — in that direct contracting case, we'd be getting Medicare fee-for-service. So unless they came right out and said, "Hey, given your strategic edge from truly investing so much time with the patient, we believe you could share in this with us," that would be quite compelling. Naturally, another angle is whether we could serve as the direct contracting entity itself. So we'll examine all of these possibilities and watch how they unfold. But that's the situation as of right now.
Gary Taylor
analystFor my final question, I'd like to get a clearer picture here, and perhaps I sound a bit behind the times. My understanding was that you had always stated 25% of Medicare involved MA. Then, if you're projecting an average of 35% for 2021, that represents a significant increase. I realize you're indicating it's closer to 28%, and a portion of that would naturally be incremental, yet it's widely recognized that MA payers reimbursed at higher rates than fee-for-service. I get why you'd prefer not to reveal that gap, but all of us had our own figures for it. So, if MA penetration were to reach 35%, we had projections for what that would mean for you regarding incremental rate and EBITDA. Thus, my question is this: has the shift to make every dialysis patient eligible for MA introduced some price compression within that existing MA book? Since it doesn't appear that, with capitation remaining so limited, the associated investments would suffice to counterbalance our projections of your incremental rate gain, so any insight on that would be appreciated.
Joel Ackerman
executiveYes. Gary, let's ensure we're all on the same page regarding the MA penetration rate. That 25 figure dates back a few years, and it increased by 2%, perhaps slightly more annually across the past few years. So at the start of — let me verify the years, at the start of 2019, that was likely about right, but you add a few percent, possibly a bit more in '19; and then once more in '20, that's how you arrive at the figure Javier mentioned, which is approaching exactly 30% by the close of 2020 and adding another 5 points in 2021. Once again, those 5 points consist of 2 points we'd have received regardless of the Cures Act, since this has been rising 2% annually, plus an additional 3% from the Cures Act. So if you're attempting to model the upside for 2021 stemming from the Cures Act taking effect, I'd go with that 3% figure.
Gary Taylor
analystUnderstood. And do you have anything to say regarding the way that has affected the rate environment? It sounds like it definitely led to additional risk-based conversations, but given that the majority of MA continues to pay fee-for-service, have you remained steady even though more volume is shifting in that direction?
Javier Rodriguez
executiveOverall, I believe the plans have devoted considerable focus to this, though that has always been the case; so it is something discussed, and the dialogue has truly evolved toward whether we can pursue value-based arrangements; but the brief response is that we had few opportunities to participate since the majority of contracts were longer term, so it remains to be seen.
Matt Larew
analystRegarding fresh facility expansion, you provided helpful background on NAG. However, when it comes to opening additional locations, perhaps you could assist us in envisioning how 2021 and 2022 may shape up. You referenced that figure declining toward the middle of 2021, then climbing again. Yet I'm simply wondering, with the elevated death rates you're observing — and clearly, from an outsider's perspective, we lack insight into the geographical specifics behind that — has this influenced your approach to constructing new centers, or any adjustment to roughly a 50/50 goal of home versus non-home?
Joel Ackerman
executiveYes. So it will shape how we consider expanding with new locations. However, there is a genuine — there is a considerable lag between when you first envision a facility and when you actually construct it and have it accredited. Consequently, I doubt you would notice a significant effect on fresh facility figures during 2021 or perhaps even 2022; nevertheless, look, those figures have declined. We accredited slightly over 80 additional locations during 2020. I believe we truly constructed somewhere within the mid-40s. And when you project ahead to the following year, once more, you will observe the accredited count drop substantially; plus the real quantity we intend to construct in the coming year will likely fall closer to the 20s. So that figure was already decreasing rapidly prior to COVID.
Matt Larew
analystYes, that's useful. And perhaps just one additional item regarding the value-based care area. I'm simply wondering whether any of your discussions have begun to incorporate considerations about progressing upstream alongside payers and the needs of the CKD population, plus making use of some of your rather strong assets such as Kidney Smart?
Javier Rodriguez
executiveYes, that's the brief response. And everyone is a novice here, which means the plans are too, and we're figuring out what that entails and what consequences arise from moving upstream. And then, naturally, there are certain regulatory limitations to handle. But ultimately, all of us are attempting to treat the patient as early as we can to ensure that, that shift goes as smoothly as it can.
Lisa Clive
analystCould you update us on where things stand regarding the timeline for the network adequacy rule litigation? Also, how likely do you believe it is that the new rule will be struck down? Then, if it isn't struck down, what would you estimate as the effect from shifting dynamics across the coming 5 years? Might MA rates for dialysis treatment decline? Or could the count of clinics fall if clinics end up — are located too far away. Clearly, that appears not to be an issue whatsoever at present, but I'm just considering a few years out.
Javier Rodriguez
executiveYes. Thank you, Lisa. Let me move up a couple of feet in case folks haven't been following it. There is a network adequacy requirement on MA plans and for dialysis patients, an objective measure involving time and distance underwent a change. And then essentially, they removed the objective criteria and rendered it more subjective rather than simply stating you must have an adequate network. The latest on that is there was essentially a technical reason and then that the case is no longer active at this moment. As we consider whether we along with community and patients will go after the next one, we are in fact waiting to confirm that we have harm. And so we're waiting to find out if a plan truly doesn't follow the spirit of ensuring there's adequacy. At present, we have not encountered any of that, and we hope that we don't. And — but that's where the update stands.
Lisa Clive
analystAll right, so the initial challenge isn't progressing anymore?
Javier Rodriguez
executiveThat's right.
Justin Lake
analystJoel, I'd like to revisit that $60 million figure you mentioned, specifically the fact that it stems completely from mortality while all other factors net out. Could you shed some light on how that $60 million evolved over the course of the year? Does it lean more toward the fourth quarter? Or was there — I'm assuming there was some negative impact in 2Q and 3Q related to mortality?
Joel Ackerman
executiveYes. There was a little in 2. It increased in 3, and roughly half of it, I believe, landed in Q4. And this is a figure that builds up, correct? Since the effect of missed treatments in Q4 ties back to our patients who died in Q2, Q3, and Q4. That's the reason it piles up in that manner, and that same pattern will carry into the first half of 2021.
Justin Lake
analystRight, that's the very reason I brought it up. So we're talking roughly $30 million. It sounds like somewhere around $10 million, $20 million, $30 million, more or less — is that how we should frame it?
Joel Ackerman
executiveCorrect.
Justin Lake
analystGiven the jump in COVID during Q4, I'm honestly taken aback that the increase was merely comparable to what we saw in 1Q, 2Q, or 3Q. By the time the year wrapped up, is there a net figure?
Joel Ackerman
executiveWhat explains that is the surge occurred across November and December. And keep in mind, as a rule, deaths trail the rise in the infection curve by 3 or 4 weeks.
Justin Lake
analystRight, that's a fair point. So perhaps you could give us a figure we might keep in mind — if, just as of year-end, considering how many patients had died, what would that figure be if you sort of, not on an annualized basis, or maybe we could discuss annualizing it, that 12/31 figure? For instance, if nobody else dies, what's the number around year-end that we're going to be seeing each quarter for the remainder of the year?
Joel Ackerman
executiveYes. That calculation isn't in front of me right now. But once more, consider how the $200 million works in this single scenario we laid out; and I want to stress once more, this is a single scenario; we believe it's a sensible middle scenario, though it might unfold in numerous different ways. But if you consider how — how to model that $200 million across the year, I think you can view it as roughly flat. The bulk of the rise in our patients dying will occur in Q1. Q1 is also more likely to carry some other expenses compared with later quarters, so the math is complicated. Perhaps Q2 comes in somewhat above Q1 because mortality is growing, yet flat throughout the year isn't an unreasonable place to start.
Justin Lake
analystUnderstood, understood. So it will ramp up a lot in Q1, and then go from roughly $30 million each quarter to somewhere around $60 million to $70 million per quarter, let's say $60 million, and possibly rise a bit beyond that before moving ahead. And that's the way you'll be up — well, actually, I've got that wrong, it won't climb by that much. It'll be $50 million, as you mentioned, or something like that in a quarter. Okay; and is there — I attempted to check the patient count. You made an acquisition, it seems, in the U.K. That will alter that figure. Is there any method by which I could get you folks to disclose that? And perhaps before we leave the call, Javier, I'm aware you had been concentrating on sort of rightsizing the international footprint. So I'm somewhat taken aback to see you pursuing additional acquisitions abroad. Perhaps you could tell us strategically why that mattered?
Javier Rodriguez
executiveCertainly. A few points. I believe we remained true to the discipline we've laid out regarding capital markets, which is essentially that we would be extremely, extremely careful about where we could bring clinical value, where we possessed the right to scale, where we had a capable management team, and we felt that, from a compliance standpoint, it was somewhere we could function safely and where we had capital efficiency. The U.K. has been transitioning from a government-led program to a private one, and it is a very compelling market that is predictable, and we understand it. And so we secured a tender, and we believe the returns will be solid.
Joel Ackerman
executiveAbsolutely. Justin, one thing I'd like to mention as well. In my view, this is an excellent pickup for the international group, and it's thrilling for them to re-enter — to move into a market that's new for us, following a period when we were trimming the platform and then holding to the principle of growing with efficient use of capital. So looked at that way, it's excellent. As far as how material it is when it comes to the effect on OI, it's quite minor.
Justin Lake
analystAnd roughly how many patients have you brought on for control?
Joel Ackerman
executiveThat figure isn't something I can recall right now; we'll check whether we can provide it to you. If we can't, you'll receive it from us following this call.
Javier Rodriguez
executiveAll right, I'll wrap up by offering a few final thoughts. First, the dedication and commitment our team shows toward keeping patients safe and healthy never wavers. It's genuinely sad and unfortunate that the age and comorbid conditions of those we treat leave them much more susceptible to COVID. We'll work hard to get as many people vaccinated as quickly as we can. Second, we laid out for you today certain dynamics the pandemic has created for our company, for our patients, and for our teams, and I hope that proved useful. Naturally, those ranges will track wherever this highly unpredictable pandemic goes. And finally, setting aside the pandemic's impact — which is a tough sentence to even say, since everything here begins with the pandemic — our business plan has demonstrated resiliency and aligns with the multiyear outlook we laid out at capital markets. So I'll finish with some optimism, hoping, as you do, that this vaccine can carry us beyond this stage. Thank you for your interest in DaVita, and we'll speak soon — stay safe.
Operator
operatorThanks. This brings today's call to a close. We appreciate everyone joining in. At this point, you're free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.